Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COBRA-light in early rheumatoid arthritis
NL-OMON26545Recruiting
- Sponsor
- Amsterdam UMC
- Start
- Feb 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of methotrexate, 5-aminosalicylic acid + sulphasalazine and prednisolone in rheumatoid arthritis (RA) (2 arms), sponsored by Amsterdam UMC. Primary endpoint: Primary: change in DAS from baseline at 6 months. Started Feb 2008; status: recruiting.
02
Drugs
methotrexate5-aminosalicylic acid + sulphasalazineprednisolone
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON26545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON26545.